tert-Butyl-DCL (PSMA inhibitor)

Tert-butyl-DCL/CAS:1025796-31-9 is a small molecule inhibitor that targets prostate-specific membrane antigen (PSMA) for potential cancer therapy. PSMA is a cell surface glycoprotein that is highly expressed in prostate cancer cells, making it a promising target for cancer treatment. Tert-butyl-DCL is designed to specifically bind to PSMA and inhibit its activity, which may lead to the suppression of prostate cancer cell growth and proliferation. This inhibitor is currently being studied in preclinical and clinical trials to evaluate its efficacy and safety as a potential treatment for prostate cancer and other PSMA-expressing cancers.

msds of tert-Butyl-DCL (PSMA inhibitor)